Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?
Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?
复制标题
癌症存活率,过度肥胖和减肥干预-我们在2020年在哪里?
DOI:
10.1038/s41416-020-01155-2
复制
发表时间:
2021-03
影响因子:
8.8
通讯作者:
UK NIHR Cancer and Nutrition Collaboration (Population Health Stream)
中科院分区:
文献类型:
--
作者:
Anderson AS;Martin RM;Renehan AG;Cade J;Copson ER;Cross AJ;Grimmett C;Keaver L;King A;Riboli E;Shaw C;Saxton JM;UK NIHR Cancer and Nutrition Collaboration (Population Health Stream)
Earlier diagnosis and more effective treatments mean that the estimated number of cancer survivors in the United Kingdom is expected to reach 4 million by 2030. However, there is an increasing realisation that excess body fatness (EBF) is likely to influence the quality of cancer survivorship and disease-free survival. For decades, the discussion of weight management in patients with cancer has been dominated by concerns about unintentional weight loss, low body weight and interventions to increase weight, often re-enforced by the existence of the obesity paradox, which indicates that high body weight is associated with survival benefits for some types of cancer. However, observational evidence provides strong grounds for testing the hypothesis that interventions for promoting intentional loss of body fat and maintaining skeletal muscle in overweight and obese cancer survivors would bring important health benefits in terms of survival outcomes and long-term impact on treatment-related side effects. In this paper, we outline the need for studies to improve our understanding of the health benefits of weight-loss interventions, such as hypocaloric healthy-eating plans combined with physical activity. In particular, complex intervention trials that are pragmatically designed are urgently needed to develop effective, clinically practical, evidence-based strategies for reducing EBF and optimising body composition in people living with and beyond common cancers.
登录
查看更多内容
DOI:
10.1093/annonc/mdu042
发表时间:
2014-10
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
作者:
Chan DSM;Vieira AR;Aune D;Bandera EV;Greenwood DC;McTiernan A;Navarro Rosenblatt D;Thune I;Vieira R;Norat T
通讯作者:
Norat T
影响因子:
6.3
作者:
Arends, Jann;Bachmann, Patrick;Preiser, Jean-Charles
通讯作者:
Preiser, Jean-Charles
影响因子:
45.3
作者:
Harrigan, Maura;Cartmel, Brenda;Irwin, Melinda L.
通讯作者:
Irwin, Melinda L.
影响因子:
4.7
作者:
Doerstling SS;O'Flanagan CH;Hursting SD
通讯作者:
Hursting SD
影响因子:
28.4
作者:
Caan, Bette J.;Feliciano, Elizabeth M. Cespedes;Chen, Wendy Y.
通讯作者:
Chen, Wendy Y.